PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10963070

Thalidomide: a comeback?

D Wendling·E Toussirot·F Michel
View original source ↗Export metadata ↓

Abstract

Thalidomide, a synthetic glutamic acid derivative first marketed in 1954 as a sedative, rapidly gained worldwide notoriety as a cause of phocomelia. To prevent further cases of this severe birth defect, thalidomide was removed from the market. Over the last few years, however, thalidomide has been found to exhibit properties of potential usefulness in a range of conditions. Trials are under way in rheumatic diseases, and safer analogs have been developed.

Explore related subjects

ContraindicationsHumansImmunosuppressive AgentsRheumatic DiseasesRheumatologyThalidomideEditorialReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D Wendling, E Toussirot, F Michel. 2000. Thalidomide: a comeback?. https://pubmed.ncbi.nlm.nih.gov/10963070/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniae.

The beta-lactam antibiotics (penicillins and cephalosporins) are commonly prescribed for the treatment of community-acquired pneumonia. However, Streptococcus pneumoniae, the most common etiologic agent of community-acquired pneumonia, has become increasingly resistant to beta-lactams over the past decade. The results of several studies suggest that penicillins remain effective for streptococcal pneumonia when the infecting pathogen has a minimal inhibitory concentration (MIC) </=2 microgram/mL, presumably because the pharmacokinetic and pharmacodynamic parameters associated with current dosing regimens are still sufficient. However, when the MIC >/=4 microgram/mL, increased rates of mortality (for patients who survive their first 4 days of hospitalization) may occur. Currently, 3.5%-7.8% of S. pneumoniae clinical isolates have MICs that fall in this latter class, but these rates may rise in the future. The clinical relevance of in vitro resistance may be related to at least 3 factors: concordance of antimicrobial therapy, severity of illness, and virulence.

Contraindications↗
PubMed2002

[Ano/rectoscopy].

Explore the source record for details and available documents.

Contraindications↗